COA Releases 2016 Community Oncology Practice Impact Report

WASHINGTON, D.C. – (October 4, 2016) – The Community Oncology Alliance (COA) today released the 2016 Community Oncology Practice Impact Report which tracks the changing landscape of cancer care in the United States. It documents a 121% increase in community cancer clinic closings and a 172% increase in consolidation into hospitals since 2008. In that period, 380 cancer treatment facilities have closed and 609 community cancer practices have been acquired by or become affiliated with hospitals. Another 390 practices report that they are struggling to stay open due to financial stresses.

 

This is the sixth Community Oncology Practice Impact Report in the series and covers activity for a nine-year period, from January 2008 through September 2016. It notes that the monthly rate of community oncology practice closures has increased 87% since the previous practice impact report.

 

“In the nine years since this report was first issued, 1,581 community oncology practices have closed, been acquired, merged or are struggling to stay open. An average of 3.6 practices have closed per month since COA began tracking this data,” said Bruce J. Gould, MD, president and medical director of Northwest Georgia Oncology Centers in Marietta, Ga., and president of COA. “Treatment advances like oral drugs and immunotherapy have the potential to save lives. That will not matter if patients can no longer afford care or if care simply disappears from their community.”

 

“We are witnessing the dismantling of the best cancer delivery system in the world when the Cancer Moonshot calls for the exact opposite,” said Ted Okon, executive director of COA. “It is no coincidence that this aligns perfectly with the enormous growth of the 340B program and misguided government experiments that continually ratchet down reimbursement. Policymakers should be alarmed at the real world impact D.C. has had on community oncology, and particularly think twice about the proposed CMS Part B experiment on cancer care. This must stop before it is too late. As the Baby Boomers age and the number of survivors increases every year, lives depend on a strong community cancer care system.

 

Compiled from public and private data sources, the 2016 Practice Impact Report provides a unique look at community oncology trends at both the national and state level. The states with the largest number of closures are Florida (37), Texas (36), and Michigan (34). The states with the most practices struggling financially are Michigan (43), New York (41), and California (40). Detailed data for all states is included in the report. 

 

Consolidation and hospital acquisition place an additional burden on the nearly 20% of Americans living in rural areas. If the only community cancer clinic in that area closes or is acquired by a hospital, local care may no longer be available. A morning treatment evolves into a daylong excursion. Access-limiting consolidation and closures make that scenario increasingly prevalent.

 

The trend of closures and consolidation of community oncology clinics into the hospital setting has had a significant and permanent impact on patient access to local, affordable cancer care. The most profound effect has been the hospital acquisition of community oncology practices, which has been fueled by the 340B drug discount program. Originally intended to support hospitals serving high numbers of indigent patients, instead, the 340B program has created a profit motive for hospitals to obtain community oncology practices.

 

Additionally, disparate site payment policies that reimburse hospitals more for the same cancer care they can receive in community practices, has contributed to this shift. The result is that patients pay up to 53% more when they receive hospital-based cancer care versus a physician office setting. That cost is borne by both the patient and the system, most often Medicare. In 2014 alone, Medicare spending would have been about $2 billion lower if the site of chemotherapy had not shifted to the hospital setting. 

 

Studies by Avalere, BRG, Milliman, and The Moran Group have shown both the higher cost of cancer care delivered in hospital settings and the impact of the 340B drug discount program. It is noteworthy that despite the severe pressures facing community cancer clinics, they lead the way in enhancing the quality of cancer care and controlling costs through new care delivery models, such as the Oncology Medical Home and Oncology Care Model.

 

The complete 2016 Community Oncology Practice Impact Report is available at http://www.communityoncology.org/2016-coa-practice-impact-report/.

 

About Community Oncology Alliance

The Community Oncology Alliance (COA) is a non-profit organization dedicated solely to preserving and protecting access to community cancer care, where the majority of Americans with cancer are treated. COA leads community cancer clinics in navigating an increasingly challenging environment to provide efficiencies, patient advocacy, and proactive solutions to Congress and policymakers. To learn more about COA visit www.CommunityOncology.org. 

COA Releases 2016 Community Oncology Practice Impact Report

COA Releases 2016 Community Oncology Practice Impact Report

News

3 years
5 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Up Next Autoplay
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Category: Non-Hodgkin Lymphoma
2 Views
ash 1 hour
REGN5458 @RutgersCancer #ASH #ASH19
REGN5458 @RutgersCancer #ASH #ASH19
Category: Multiple Myeloma
0 Views
ash 2 hours
Phase 3 ICARIA-MM trial of isatuximab #ASH19 #ASH @sanofi
Phase 3 ICARIA-MM trial of isatuximab #ASH19 #ASH @sanofi
Category: Multiple Myeloma
0 Views
ash 10 hours
CARTITUDE-1: How is This Different from Others? @MountSinaiNYC @DMadduri #ASH19 #ASH
CARTITUDE-1: How is This Different from Others? @MountSinaiNYC @DMadduri #ASH19 #ASH
Category: Multiple Myeloma
2 Views
ash 10 hours
CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528 @MountSinaiNYC @DMadduri
CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528 @MountSinaiNYC @DMadduri
Category: Multiple Myeloma
2 Views
ash 10 hours
CAR-T Cell Imaging Markers: How This Affects Clinicians @PennMedicine
CAR-T Cell Imaging Markers: How This Affects Clinicians @PennMedicine
Category: Immunotherapy
0 Views
Cancer-News 11 hours
How Sensitive is the Technology? @PennMedicine @sellmyerlab
How Sensitive is the Technology? @PennMedicine @sellmyerlab
Category: Immunotherapy
0 Views
Cancer-News 11 hours
CAR-T Cells With Imaging Markers @PennMedicine sellmyerlab @sellmyerlab
CAR-T Cells With Imaging Markers @PennMedicine sellmyerlab @sellmyerlab
Category: Immunotherapy
0 Views
Cancer-News 11 hours
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Category: Chronic Myelogenous Leukemia
4 Views
iCMLf 1 day
Perspectives on the Future of CML
Perspectives on the Future of CML
Category: Chronic Myelogenous Leukemia
2 Views
iCMLf 1 day